Thyrocare Technologies Limited has released the transcript of its post-results earnings conference call held on January 28, 2026, with analysts and investors. The call featured insights from MD & CEO Rahul Guha, CFO Vikram Gupta, and other senior management. Key highlights from the call included the onboarding of Dr. Ramesh Kinha as Chief Operating Officer and Rajdeep Panwar as Chief Commercial Officer. The company also announced Madhuri Dixit as its new brand ambassador to enhance trust and communicate quality. Thyrocare received two national honors at the National Diagnostics Forum & Awards: Best Diagnostic Chain of the Year and Patient-Centric Diagnostic Company of the Year. The franchise business showed strong growth, reaching its highest level ever with 10,300 active quarterly franchisees as of Q3 FY'26, a 200 franchisee increase in the quarter. Quality remains a top priority, with the company achieving Six Sigma level quality, reducing complaints per million tests to 3.2, a 43% year-on-year decrease. New technologies like histopathology, an HPLC platform, coagulation tests, and the BioFire PCR platform have been added. Allergy panels are now included free of cost in their Aarogyam packages. Financially, consolidated revenue grew by 18% year-on-year to INR 196 crore, with the pathology business growing 20% and the franchisee business up 12%. Consolidated normalized EBITDA margin stood at 32%, a 26% year-on-year increase. Standalone revenue was INR 183 crore, a 20% year-on-year growth. The company processed 49.6 million tests in Q3 FY'26, serving 4.5 million patients. Management reiterated their strategy to be the B2B partner of choice, offering low-cost, robust testing solutions. They anticipate mid-teen growth for the franchise business and 1.5x that for partnerships in the long term. Investments are being made in areas like genomics and allergy testing.
